Ali Azargoonjahromi

16PUBLICATIONS
4CO-AUTHORS
Molecular medicinePsycholinguistics (incl. speech production and comprehension)Central nervous systemMemory and attentionNaturopathy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Oct 04, 2025
Efficacy and Safety of KarXT (Xanomeline-Trospium; Cobenfy™) in Schizophrenia: A Systematic and Meta-Analysis Review of Randomized Controlled Trials.

Ali Azargoonjahromi, Hamide Nasiri

|Aug 15, 2025
Plasma and CSF Amyloid-β42 Predict Plasma Sortilin, Which Influences Cognitive Impairment via Mediation of Whole-Brain Volume: A 12-Month Longitudinal Study Across the Alzheimer's Disease Spectrum.

Ali Azargoonjahromi

|Jul 29, 2025
Higher p-Cresol sulfate and tumor necrosis factor (TNF)-α levels are associated with cognitive improvement through increased TNF receptor 2 in individuals with mild cognitive impairment: A cross-sectional mediation analysis.

Ali Azargoonjahromi, Hamide Nasiri

|Jul 02, 2025
CSF Amyloid-β42 associates with neuropsychiatric and cognitive outcomes via cerebral glucose metabolism.

Ali Azargoonjahromi, Hamide Nasiri

|Mar 20, 2025
Elevated CSF GAP-43 in Mild Cognitive Impairment Linked to Cognitive Impairment Through Increased Amyloid-β Accumulation, with a Shift to Reduced Amyloid-β Accumulation in Alzheimer's Disease.

Ali Azargoonjahromi, Mortaza Eivazi, Hamide Nasiri

|Mar 04, 2025
Plasma tryptophan levels are linked to hippocampal integrity and cognitive function in individuals with mild cognitive impairment.

Ali Azargoonjahromi

Pageof 3

Frequent Collaborators

3 joint publications

Hamide Nasiri

1 joint publications

Mohammad Sadeghi

1 joint publications

Mahsa Mayeli

1 joint publications

Vahideh Tarhriz